|
1
|
Libby P, Ridker PM and Maseri A:
Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gram J: Inflammation in atherosclerosis
and acute coronary syndromes. Int Congr Ser. 1229:95–102. 2002.
View Article : Google Scholar
|
|
3
|
Kaperonis EA, Liapis CD, Kakisis JD,
Dimitroulis D and Papavassiliou VG: Inflammation and
atherosclerosis. Eur J Vasc Endovasc Surg. 31:386–393. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yasojima K, Schwab C, McGeer EG and McGeer
PL: Generation of C-reactive protein and complement components in
atherosclerotic plaques. Am J Pathol. 158:1039–1051. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ridker PM: Clinical application of
C-reactive protein for cardiovascular disease detection and
prevention. Circulation. 107:363–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bermudez EA, Rifai N, Buring J, Manson JE
and Ridker PM: Interrelationships among circulating interleukin-6,
C-reactive protein and traditional cardiovascular risk factors in
women. Arterioscler Thromb Vasc Biol. 22:1668–1673. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lind L: Circulating markers of
inflammation and atherosclerosis. Atherosclerosis. 169:203–214.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han SH, Quon MJ and Koh KK: Beneficial
vascular and metabolic effects of peroxisome proliferator-activated
receptor-α activators. Hypertension. 46:1086–1092. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marchesi C and Schiffrin EL: Peroxisome
proliferator-activated receptors and the vascular system: Beyond
their metabolic effects. J Am Soc Hypertens. 2:227–238. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moraes LA, Piqueras L and Bishop-Bailey D:
Peroxisome proliferator-activated receptors and inflammation.
Pharmacol Ther. 110:371–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bouhlel MA, Staels B and Chinetti-Gbaguidi
G: Peroxisome proliferator-activated receptors - from active
regulators of macrophage biology to pharmacological targets in the
treatment of cardiovascular disease. J Intern Med. 263:28–42.
2008.PubMed/NCBI
|
|
12
|
Marx N, Sukhova G, Murphy C, Libby P and
Plutzky J: Macrophages in human atheroma contain PPARgamma:
Differentiation-dependent peroxisomal proliferator-activated
receptor gamma (PPARgamma) expression and reduction of MMP-9
activity through PPARgamma activation in mononuclear phagocytes in
vitro. Am J Pathol. 153:17–23. 1998.PubMed/NCBI
|
|
13
|
Shu H, Wong B, Zhou G, Li Y, Berger J,
Woods JW, Wright SD and Cai TQ: Activation of PPARalpha or gamma
reduces secretion of matrix metalloproteinase 9 but not interleukin
8 from human monocytic THP-1 cells. Biochem Biophys Res Commun.
267:345–349. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Galis ZS and Khatri JJ: Matrix
metalloproteinases in vascular remodeling and atherogenesis: The
good, the bad and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI
|
|
15
|
Olson FJ, Schmidt C, Gummesson A,
Sigurdardottir V, Hulthe J, Wiklund O and Fagerberg B: Circulating
matrix metalloproteinase 9 levels in relation to sampling methods,
femoral and carotid atherosclerosis. J Intern Med. 263:626–635.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eidelman RS and Hennekens CH: Fibrinogen:
A predictor of stroke and marker of atherosclerosis. Eur Heart J.
24:499–500. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tribouilloy C, Peltier M, Colas L, Senni
M, Ganry O, Rey JL and Lesbre JP: Fibrinogen is an independent
marker for thoracic aortic atherosclerosis. Am J Cardiol.
81:321–326. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Luca G, Verdoia M, Cassetti E, Schaffer
A, Cavallino C, Bolzani V and Marino P: Novara Atherosclerosis
Study Group (NAS): High fibrinogen level is an independent
predictor of presence and extent of coronary artery disease among
Italian population. J Thromb Thrombolysis. 31:458–463. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo F, Liu J, Wang C, Liu N and Lu P:
Fibrinogen, fibrin, and FDP induce C-reactive protein generation in
rat vascular smooth muscle cells: Pro-inflammatory effect on
atherosclerosis. Biochem Biophys Res Commun. 390:942–946. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu PP, Liu JT, Liu N, Guo F, Ji YY and
Pang X: Pro-inflammatory effect of fibrinogen and FDP on vascular
smooth muscle cells by IL-6, TNF-α and iNOS. Life Sci. 88:839–845.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hadrava V, Tremblay J and Hamet P:
Abnormalities in growth characteristics of aortic smooth muscle
cells in spontaneously hypertensive rats. Hypertension. 13:589–597.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davalos D and Akassoglou K: Fibrinogen as
a key regulator of inflammation in disease. Semin Immunopathol.
34:43–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bini A, Fenoglio JJ Jr, Mesa-Tejada R,
Kudryk B and Kaplan KL: Identification and distribution of
fibrinogen, fibrin and fibrin(ogen) degradation products in
atherosclerosis Use of monoclonal antibodies. Arteriosclerosis.
9:109–121. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Maat MPM, Pietersma A, Kofflard M,
Sluiter W and Kluft C: Association of plasma fibrinogen levels with
coronary artery disease, smoking and inflammatory markers.
Atherosclerosis. 121:185–191. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lominadze D, Dean WL, Tyagi SC and Roberts
AM: Mechanisms of fibrinogen-induced microvascular dysfunction
during cardiovascular disease. Acta Physiol (Oxf). 198:1–13. 2010.
View Article : Google Scholar
|
|
26
|
Guo M, Sahni SK, Sahni A and Francis CW:
Fibrinogen regulates the expression of inflammatory chemokines
through NF-kappaB activation of endothelial cells. Thromb Haemost.
92:858–866. 2004.PubMed/NCBI
|
|
27
|
Sen U, Tyagi N, Patibandla PK, Dean WL,
Tyagi SC, Roberts AM and Lominadze D: Fibrinogen-induced
endothelin-1 production from endothelial cells. Am J Physiol Cell
Physiol. 296:C840–C847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jensen T, Kierulf P, Sandset PM,
Klingenberg O, Joø GB, Godal HC and Skjønsberg OH: Fibrinogen and
fibrin induce synthesis of proinflammatory cytokines from isolated
peripheral blood mononuclear cells. Thromb Haemost. 97:822–829.
2007.PubMed/NCBI
|
|
29
|
Smiley ST, King JA and Hancock WW:
Fibrinogen stimulates macrophage chemokine secretion through
toll-like receptor 4. J Immunol. 167:2887–2894. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soskić SS, Dobutović BD, Sudar EM,
Obradović MM, Nikolić DM, Zarić BL, Stojanović SD, Stokić EJ,
Mikhailidis DP and Isenović ER: Peroxisome proliferator-activated
receptors and atherosclerosis. Angiology. 62:523–534. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Plutzky J: Medicine. PPARs as therapeutic
targets: Reverse cardiology? Science. 302:406–407. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ricote M, Li AC, Willson TM, Kelly CJ and
Glass CK: The peroxisome proliferator-activated receptor-gamma is a
negative regulator of macrophage activation. Nature. 391:79–82.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang C, Ting AT and Seed B: PPAR-gamma
agonists inhibit production of monocyte inflammatory cytokines.
Nature. 391:82–86. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galis ZS, Sukhova GK, Lark MW and Libby P:
Increased expression of matrix metalloproteinases and matrix
degrading activity in vulnerable regions of human atherosclerotic
plaques. J Clin Invest. 94:2493–2503. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tayebjee MH, Tan KT, MacFadyen RJ and Lip
GYH: Abnormal circulating levels of metalloprotease 9 and its
tissue inhibitor 1 in angiographically proven peripheral arterial
disease: Relationship to disease severity. J Intern Med.
257:110–116. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaneider NC, Mosheimer B, Günther A,
Feistritzer C and Wiedermann CJ: Enhancement of
fibrinogen-triggered pro-coagulant activation of monocytes in vitro
by matrix metalloproteinase-9. Thromb J. 8:2–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
